Competition law is no longer a standalone legal discipline within the life science sector. As antitrust scrutiny expands across patent practices, litigation settlements, pricing and deal-making, competition risk has become an increasingly important strategic issue, with significant potential implications for how you and your company approach future IP, regulatory and corporate decision-making.
This holistic, industry-led keynote will bring together private practitioners, regulators and in-house counsel to examine the evolving landscape of life science antitrust and discuss how recent developments in this area are reshaping legal strategy across the sector.
- How are interactions between competition authorities, patent offices and healthcare agencies reshaping the legal operating landscape for life science companies?
- How are industry perspectives on M&As, settlements and other life science transactions evolving?
- How are regulators scrutinising IP and regulatory frameworks in abuse of dominance investigations?
- What global trends are emerging in dawn raids, antitrust litigation and financial enforcement mechanisms targeting anti-competitive conduct in the life sciences sector?
- How should legal teams integrate competition risk into broader IP, regulatory and corporate strategy?
Agenda Track No.:
Track 4
Session Type:
General Session (Presentation)
Force Inline Description:
0